#United States #Lexington #Partner Therapeutics #NRG1 #BIZENGRI®

Partner Therapeutics Achieves Historic FDA Approval for BIZENGRI®

On May 11, 2026, Partner Therapeutics, Inc. (PTx), a fully integrated biotechnology company, celebrated a significant milestone with the FDA's approval of BIZENGRI® (zenocutuzumab-zbco). This breakthrough treatment is aimed at adults suffering from advanced, unresectable or metastatic cholangiocarcinoma marked by the presence of a neuregulin 1 (NRG1) gene fusion. This authorization comes amid pressing clinical needs as there were previously no approved targeted therapies specifically available for patients within this category.

The FDA's expedited approval followed PTx’s receipt of a Commissioner's National Priority Voucher (CNPV), which facilitated a faster review process. This decision underscores the urgent healthcare need to provide effective options for patients diagnosed with this aggressive cancer type— cholangiocarcinoma, which presently has a dismal 5-year survival rate of less than 15% across all stages.

Significance of the Approval

In a statement, Pritesh J. Gandhi, Chief Development Officer of Partner Therapeutics, highlighted the gravity of this achievement. "Today's FDA approval of BIZENGRI for NRG1 fusion-positive cholangiocarcinoma is a historic milestone for patients who have had no approved targeted therapy. We are grateful to the patients, families, and investigators for their involvement in the eNRGy trial which provided compelling evidence of the treatment's effectiveness and tolerability."

The foundation for this approval rests on clinical data derived from the eNRGy trial—a multicenter, open-label Phase 2 clinical trial that evaluated patients with NRG1 fusion-positive tumors. The trial saw participation from a total of 22 patients with unresectable or metastatic cholangiocarcinoma, with 19 providing evaluable data on efficacy. Outcomes revealed a confirmed overall response rate (ORR) of 36.8%, with responses lasting from 2.8 to 12.9 months, offering hope to a demographic that has few treatment alternatives.

Adverse Reactions and Safety Profile

As is common with new treatments, BIZENGRI came with a spectrum of adverse reactions. Among the most frequently reported side effects (occurring in more than 20% of patients) were fatigue, diarrhea, musculoskeletal pain, and abdominal issues. Importantly, the trial noted that less than 1% of participants discontinued the medication due to adverse events, indicating BIZENGRI's manageable safety profile.

Importance of Molecular Testing

Clinical experts have emphasized the need for comprehensive molecular testing for detecting rare gene fusions such as NRG1. Dr. James Cleary, Director of Clinical Research at Dana-Farber Cancer Institute, remarked, "NRG1 fusion-positive cholangiocarcinoma represents a rare but clinically important subset of disease with limited therapeutic options and poor outcomes. The clinical data from the eNRGy study support the role of zenocutuzumab as a targeted treatment in this challenging landscape."

This approval not only serves as an essential therapeutic avenue for NRG1 fusion-positive cholangiocarcinoma but also opens dialogue surrounding the importance of precision medicine and tailored treatments in oncology. BIZENGRI further positions itself within the broader context of targeted cancer therapies, having already achieved approval for treating advanced non-small cell lung cancer and pancreatic adenocarcinoma where NRG1 fusions are indicated.

Conclusion

With BIZENGRI's approval, Partner Therapeutics aims to make substantial strides toward improving patient outcomes by ensuring timely access to the treatment. The commitment to work collaboratively with the oncology community at large affirms their dedication to patient care, and the continued effort in clinical research is poised to transform the future landscape of cancer therapies.

For additional details about the eNRGy trial and producers, visit Partner Therapeutics.